Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors.
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 455
- Registration Number
- NCT04116541
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 14
- Registration Number
- NCT04091750
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 7
- Registration Number
- NCT04066595
- Locations
- 🇩🇪
Department of Urology of the University Medical Center Mainz, Mainz, Germany
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 22
- Registration Number
- NCT04022343
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 26
- Registration Number
- NCT03967522
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
🇫🇷CHU Besancon, Besançon, France
🇫🇷CHU Bordeaux, Bordeaux, France
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Duke University
- Target Recruit Count
- 3
- Registration Number
- NCT03964337
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Yousef Zakharia
- Target Recruit Count
- 62
- Registration Number
- NCT03957551
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 127
- Registration Number
- NCT03945773
- Locations
- 🇳🇱
Maxima Medisch Centrum, Eindhoven, Netherlands
🇨🇭Kantonsspital St. Gallen, Saint Gallen, Switzerland
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-02-25
- Target Recruit Count
- 37
- Registration Number
- NCT03943602
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 855
- Registration Number
- NCT03937219
- Locations
- 🇺🇸
Exelixis Clinical Site #29, Boca Raton, Florida, United States
🇺🇸Exelixis Clinical Site #58A, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #12, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.